Changing trends in clinical AIDS presentations and survival among HIV-1-infected women

Journal of Women's Health

Volumn 13, Issue 6, 2004, Pages 719-730

  Charurat, Manhattan ^a,n   Blattner, William ^a   Hershow, Ron ^b   Buck, Arlene ^c   Zorrilla, Carmen D ^d   Watts, D Heather ^e   Paul, Mary ^f   Landesman, Sheldon ^g   Adeniyi Jones, Samuel ^h   Tuomala, Ruth ^c   Diaz, Clemente ^d   Pacheco Acosta, Edna ^d   Cooper, Ellen ⁱ   Mesthene, Donna ⁱ   Pitt, Jane ^j   Higgins, Alice ^j   Handelsman, Edward ^g   Moroso, Gail ^g   Rich, Kenneth ^k   Turpin, Delmyra ^k   Shearer, William ^f   Pacheco, Susan ^f   Cooper, Norma ^f   Rosario, Joana ^h   Nugent, Robert ^e   Smeriglio, Vincent ^l   Davenny, Katherine ^l   Thompson, Bruce ^m   more..

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g STATE UNIVERSITY OF NEW YORK   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ Boston/Worcester Site   (United States)

^j New York Presbyterian Hospital Columbia University Medical Center   (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^l NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^m Clinical Trials & Surveys Corp   (United States)

ⁿ Clinical Trials/Surveys Corp ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; ISONIAZID; PENTAMIDINE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDA; CANDIDIASIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MORBIDITY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK REDUCTION; SURVIVAL; TUBERCULOSIS; WASTING SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MIDDLE AGED; POISSON DISTRIBUTION; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 4644235955     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2004.13.719     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. Trends in sexual risk behaviors among high school students - United States, 1991-2001. MMWR 2002;51: 856.
2. Cohn SE. Women with HIV/AIDS: Treating the fastest-growing population. AIDS Read 2003;13:241, 244.
3. Centers for Disease Control and Prevention. Persons reported to be living with HIV infection and AIDS, as of December 2001. HIV/AIDS Surveillance Report 2002;13.
4. Campisi G, Pizzo G, Mancuso S, Margiotta V. Gender differences in human immunodeficiency virus-related oral lesions: An Italian study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:546.
5. Greenspan D, Komaroff E, Redford M, et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2000;25:44.
6. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510.
7. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720.
8. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484.
9. Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996;10:273.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1.
11. Minkoff H, Hershow R, Watts DH, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol 2003; 189:552.
12. Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies, 2nd ed. Lyon, France: International Agency for Research on Cancer, 1987.
13. STATA version 7. STATA Corporation, College Station, TX.
14. SAS version 8.2. SAS, Cary, NC.
15. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15:347.
16. Gange SJ, Barron Y, Greenblatt RM, et al. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health 2002;56:153.
17. Moore RD, Chaisson RE. Natural history of HIV infections in the era of combination antiretroviral therapy. AIDS 1999;13:1933.
18. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999;48:1.
19. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5.
20. Palella FJ, Delaney KM, Moorman AC, et al., and The HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853.
21. Forrest DM, Seminari E, Hogg RS, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998;27:1379.
22. Mocroft A, Katlama C, Johnson AM. AIDS across Europe 1994-98: The EUROSIDA study. Lancet 2000; 356:291.
23. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. 1999;11:1.
24. Sullivan J, Moore R, Keruly J, Chaisson R. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000;162:64.
25. Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA 1994;272:455.
26. Tumbarello M, Tacconelli E, de Gaetano K, et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr 1998;18:39.
27. Salomon N, Perlman DC, Friedmann P, Ziluck V, Des J. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis 2000;4:47.
28. Mientjes GH, van Ameijden EJ, van den Hoek AJ, Coutinho RA. Increased morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam. AIDS 1992;6:207.
29. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988;2:267.
30. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697.
31. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV-infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Br Med J 1990;301:1362.
32. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573.
33. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175.
34. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 2002;40:341.
35. Raufman JP, Rosenthal L. Oral candidiasis as a marker for esophageal candidiasis in the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:54.
36. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;13:1249.
37. Hu D, Fleming PL, Castro KG. How important is race/ethnicity as an indicator of risk for specific AIDS defining conditions? J Acquir Immune Defic Syndr 2003;10:374.
38. Jones JL, Hanson DL, Dworkin MS, Kaplan JE, Ward JW. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. J Infect Dis 1998;178: 114.
39. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989;321:874.
40. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/adolescent spectrum of disease group. AIDS 1999;13:1687.
41. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001;285:1308.
42. Li Y, McDonald AM, Dore GJ, Kaldor JM. Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee. AIDS 2000;14: 2349.
43. Ahdieh L, Gange S, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy usage in a large cohort of HIV-infected women. Am J Epidemiol 2000;152:923.